These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31888528)

  • 1. Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study.
    Glaser RL; York AE; Dimitrakakis C
    BMC Cancer; 2019 Dec; 19(1):1271. PubMed ID: 31888528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study.
    Glaser RL; Dimitrakakis C
    Maturitas; 2013 Dec; 76(4):342-9. PubMed ID: 24028858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study.
    Donovitz G; Cotten M
    Eur J Breast Health; 2021 Apr; 17(2):150-156. PubMed ID: 33870115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone and breast cancer prevention.
    Glaser R; Dimitrakakis C
    Maturitas; 2015 Nov; 82(3):291-5. PubMed ID: 26160683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy.
    Dimitrakakis C; Jones RA; Liu A; Bondy CA
    Menopause; 2004; 11(5):531-5. PubMed ID: 15356405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer.
    Glaser RL; Dimitrakakis C
    Menopause; 2014 Jun; 21(6):673-8. PubMed ID: 24149917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.
    Tamimi RM; Hankinson SE; Chen WY; Rosner B; Colditz GA
    Arch Intern Med; 2006 Jul; 166(14):1483-9. PubMed ID: 16864758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial.
    Mattar A; Logullo AF; Facina G; Nonogaki S; Soares FA; Gebrim LH
    J Cancer Res Clin Oncol; 2011 May; 137(5):897-905. PubMed ID: 20886231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum sex hormone levels after menopause and subsequent breast cancer.
    Berrino F; Muti P; Micheli A; Bolelli G; Krogh V; Sciajno R; Pisani P; Panico S; Secreto G
    J Natl Cancer Inst; 1996 Mar; 88(5):291-6. PubMed ID: 8614008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
    Baum M; Budzar AU; Cuzick J; Forbes J; Houghton JH; Klijn JG; Sahmoud T;
    Lancet; 2002 Jun; 359(9324):2131-9. PubMed ID: 12090977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California.
    Ereman RR; Prebil LA; Mockus M; Koblick K; Orenstein F; Benz C; Clarke CA
    BMC Public Health; 2010 Apr; 10():228. PubMed ID: 20433756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone pellet insertion.
    Mechlin CW; Frankel J; McCullough A
    J Sex Med; 2014 Jan; 11(1):254-61. PubMed ID: 24119010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy.
    Glaser RL; York AE
    Int J Pharm Compd; 2019; 23(4):325-339. PubMed ID: 31315085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
    Goss PE; Ingle JN; Pritchard KI; Ellis MJ; Sledge GW; Budd GT; Rabaglio M; Ansari RH; Johnson DB; Tozer R; D'Souza DP; Chalchal H; Spadafora S; Stearns V; Perez EA; Liedke PE; Lang I; Elliott C; Gelmon KA; Chapman JA; Shepherd LE
    J Clin Oncol; 2013 Apr; 31(11):1398-404. PubMed ID: 23358971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
    Kaufmann M; Jonat W; Hilfrich J; Eidtmann H; Gademann G; Zuna I; von Minckwitz G
    J Clin Oncol; 2007 Jul; 25(19):2664-70. PubMed ID: 17563395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
    Cristofanilli M; Valero V; Mangalik A; Royce M; Rabinowitz I; Arena FP; Kroener JF; Curcio E; Watkins C; Bacus S; Cora EM; Anderson E; Magill PJ
    Clin Cancer Res; 2010 Mar; 16(6):1904-14. PubMed ID: 20215537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
    Cuzick J; Sestak I; Baum M; Buzdar A; Howell A; Dowsett M; Forbes JF;
    Lancet Oncol; 2010 Dec; 11(12):1135-41. PubMed ID: 21087898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
    Iwase T; Saji S; Iijima K; Higaki K; Ohtani S; Sato Y; Hozumi Y; Hasegawa Y; Yanagita Y; Takei H; Tanaka M; Masuoka H; Tanabe M; Egawa C; Komoike Y; Nakamura T; Ohtsu H; Mukai H
    J Clin Oncol; 2023 Jun; 41(18):3329-3338. PubMed ID: 37079878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.
    Ward MC; Vicini F; Chadha M; Pierce L; Recht A; Hayman J; Thaker NG; Khan A; Keisch M; Shah C
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):296-306. PubMed ID: 31212043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.